Cytokinetics | CYTK - Operating Profit


Cytokinetics reported $-181.23M in Operating Profit for its fiscal quarter ending in March of 2026.





Operating Profit Change Date
Acadia Pharmaceuticals USD 37.84M 42.45M Jun/2026
Amgen USD 4.61B 777M Jun/2026
Arca Biopharma USD -36.43M 2M Mar/2026
Bayer EUR 3.53B 2.42B Mar/2026
Biogen USD -243.8M 758.1M Jun/2026
Brainstorm Cell Therapeutics USD -2.05M 198K Mar/2026
Bristol-Myers Squibb USD 299M 3.07B Jun/2026
Capricor Therapeutics USD -29.16M 2.87M Dec/2025
Cytokinetics USD -181.23M 2.86M Mar/2026
Eisai JPY 24.73B 35.04B Jun/2026
Eli Lilly USD 12.46B 2.68B Jun/2026
Exelixis USD 251.34M 15.43M Mar/2026
Geron USD -236K 10.55M Mar/2026
Halozyme Therapeutics USD -61.77M 26.64M Mar/2026
Ionis Pharmaceuticals USD -102.29M 15.71M Jun/2026
Ligand Pharmaceuticals USD 56.62M 3.7M Jun/2026
Merck USD 840M 2.72B Jun/2026
Novartis USD 4.75B 515M Jun/2026
Pfizer USD 667M 4.32B Jun/2026
Regeneron Pharmaceuticals USD 1.42B 675.7M Jun/2026
Roche Holding CHF 11.46B 1.91B Jun/2026
Sanofi EUR 2.38B 449M Jun/2026